Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer is a research paper published in Frontiers in Oncology (2023). On theSindex it has a DataRank of 0. It has been cited 9 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: P30 CA008748
NCI NIH HHS
Grant: R01 CA251591
Loxo Oncology
FWCI
1.48
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals
Additional file 1 of Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer
Additional file 1 of Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer